FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to obtaining Clostridium difficile immunogenic mutant toxines, and may be used in medicine for treating C. difficile infection in a mammal. Mutant toxin includes glucosyltransferase domain with at least one mutation, and cysteineprotease domain with at least one mutation in comparison with appropriate toxin C. difficile of wild type. These mutant toxins additionally include at least one amino acid chosen from lysine, glutamic acid, aspartic acid or chemically cross-linked using formaldehyde, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS) or a combination of EDC/NHS.
EFFECT: invention allows effectively induce neutralising antibody against C.difficile toxin.
21 cl, 25 dwg, 61 tbl, 45 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS RELEVANT TO MUTANT TOXIN FROM CLOSTRIDIUM DIFFICILE | 2013 |
|
RU2630671C2 |
| COMPOSITIONS RELATED TO MUTANT TOXIN CLOSTRIDIUM DIFFICILE AND THEIR APPLICATION METHODS | 2012 |
|
RU2754446C2 |
| COMPOSITIONS RELATED TO MUTANT TOXIN CLOSTRIDIUM DIFFICILE AND THEIR APPLICATION METHODS | 2017 |
|
RU2773880C1 |
| ANTIBODIES FOR TREATMENT OF INFECTION AND DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE | 2011 |
|
RU2630663C9 |
| ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
| ANTI-POISONING MEDICATION | 2007 |
|
RU2465893C2 |
| COMPOSITION FOR PREVENTING AND/OR TREATING INFECTION, CAUSED BY HIV-1 | 2012 |
|
RU2603262C2 |
| MUTANT VIRUS OF BULL DIARRHEA | 2006 |
|
RU2394594C2 |
| ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY | 2013 |
|
RU2656153C1 |
| SUBSTANCES AND METHODS FOR USE IN THE PREVENTION AND/OR TREATMENT OF HUNTINGTON'S DISEASE | 2015 |
|
RU2742493C2 |
